Innovation and crowdsourcing in clinical trials: Interview with Dr Tomasz Sablinski
Clinical Trial News Wednesday, July 25th, 2012Pharmaphorum.com: 7/24/12.
Angela Dunn interviews Dr Tomasz Sablinski
Angela Dunn interviews Dr Tomasz Sablinski, the Founder and CEO of Transparency Life Sciences, the world’s first drug development company based on Open Innovation (OI).
According to the “2012 State of Global Open Innovation“, Forrester defines Open Innovation (OI) as:
“Innovation efforts that leverage external partners, ideas, or problem solvers to contribute to internal innovation initiatives.”
Transparency Life Sciences is the world’s first drug development company based on Open Innovation. The goal of the new start-up is “to develop medicines for significant unmet medical needs by acquiring promising drug compounds, designing studies via crowdsourced methods, and conducting those clinical studies with unmatched productivity.”
Here, Angela Dunn interviews Dr Tomasz Sablinski, the Founder and CEO of Transparency Life Sciences on crowdsourcing for Open Innovation and how, despite gaining momentum in other industries, it is new to drug development. Read more
